Botox-maker Allergan Plc said on Wednesday its quarterly net sales rose 11.4 percent on higher demand for its medical aesthetics products.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Net loss attributable to shareholders was $4.03 billion, or $12.07 per share, in the third quarter ended Sept. 30, compared with a profit of $15.15 billion, or $38.58 per share, a year earlier.

The company said it took an impairment charge of $3.2 billion related to its dry-eye drug Restasis, as well as $1.3 billion in impairment charge related to Teva securities.

Net revenue rose 11.4 percent to $4.03 billion.

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)